Literature DB >> 12126226

Central nervous system adverse effects with efavirenz: case report and review.

Talia Puzantian1.   

Abstract

Efavirenz is a nonnucleoside reverse transcriptase inhibitor that can be given with other antiretroviral agents for the treatment of human immunodeficiency virus infection. A 47-year-old man with acquired immunodeficiency syndrome developed severe depression and suicidal ideation necessitating psychiatric hospitalization and antidepressant therapy. The symptoms occurred in temporal relation to the introduction of efavirenz into his highly active antiretroviral therapy regimen. Similar serious psychiatric adverse effects have been associated with this agent. Clinicians should monitor for central nervous system adverse effects in all patients taking efavirenz.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12126226     DOI： 10.1592/phco.22.11.930.33624

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN： 0277-0008            Impact factor:   4.705


  12 in total

1.  Long-term efficacy and safety of efavirenz dose reduction to 200 mg once daily in a Caucasian patient with HIV.

Authors:  Salvador Cabrera Figueroa; Alicia Iglesias Gómez; Almudena Sánchez Martín; María de la Paz Valverde Merino; Alfonso Domínguez-Gil Hurlé; Miguel Cordero Sánchez
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

Review 2.  Neuropsychiatric complications of antiretroviral therapy.

Authors:  Michelle S Cespedes; Judith A Aberg
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

3.  Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data.

Authors:  Katie R Mollan; Marlene Smurzynski; Joseph J Eron; Eric S Daar; Thomas B Campbell; Paul E Sax; Roy M Gulick; Lumine Na; Lauren O'Keefe; Kevin R Robertson; Camlin Tierney
Journal:  Ann Intern Med       Date:  2014-07-01       Impact factor: 25.391

4.  Neuropsychiatric sequelae in an efavirenz treated patient with hepatitis B.

Authors:  Emma Salter; Anish S Patel
Journal:  BMJ Case Rep       Date:  2009-11-26

5.  The dual modulatory effects of efavirenz on GABAA receptors are mediated via two distinct sites.

Authors:  Renqi Huang; Zhenglan Chen; Sean Dolan; John A Schetz; Glenn H Dillon
Journal:  Neuropharmacology       Date:  2017-04-27       Impact factor: 5.250

6.  Population pharmacokinetic/pharmacogenetic model for optimization of efavirenz therapy in Caucasian HIV-infected patients.

Authors:  Almudena Sánchez; Salvador Cabrera; Dolores Santos; M Paz Valverde; Aurelio Fuertes; Alfonso Domínguez-Gil; María J García
Journal:  Antimicrob Agents Chemother       Date:  2011-09-06       Impact factor: 5.191

Review 7.  Medical consequences of drug abuse and co-occurring infections: research at the National Institute on Drug Abuse.

Authors:  Jag H Khalsa; Glenn Treisman; Elinore McCance-Katz; Ellen Tedaldi
Journal:  Subst Abus       Date:  2008       Impact factor: 3.716

8.  Incidence and predictors of adverse drug events in an African cohort of HIV-infected adults treated with efavirenz.

Authors:  Isaac Okoh Abah; Maxwell Akanbi; Mercy Enuwa Abah; Amos Istifanus Finangwai; Christy W Dady; Kakjing Dadul Falang; Augustine Odoh Ebonyi; Joseph Anejo Okopi; Oche Ochai Agbaji; Altiene Solomon Sagay; Prosper Okonkwo; John A Idoko; Phyllis J Kanki
Journal:  Germs       Date:  2015-09-01

Review 9.  Beneficial and Adverse Effects of cART Affect Neurocognitive Function in HIV-1 Infection: Balancing Viral Suppression against Neuronal Stress and Injury.

Authors:  Nina Y Yuan; Marcus Kaul
Journal:  J Neuroimmune Pharmacol       Date:  2019-08-06       Impact factor: 4.147

10.  Efavirenz poisoning in a 12 year old HIV negative African boy.

Authors:  Rose Nazziwa; Moorine Sekadde; Francis Kanyike; Eric Wobudeya; Nicolette Nabukeera-Barungi
Journal:  Pan Afr Med J       Date:  2012-07-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.